THE MBL77 DIARIES

Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit ample to tolerate FCR therapy, should be very good candidates for the latter, While using the gain currently being that this treatment is usually concluded in 6 months while ibrutinib must be taken indefinitely. This feature can be especially precious for non-compliant pa